MTCH1 and neoplasm: Given that Sorafenib is a multi-target drug and ferroptosis inducible antitumor agent [41, 42], and that MTCH1 inactivation triggers ferroptosis, we investigated whether targeting MTCH1 in combination with Sorafenib could produce an additive effect on inhibiting tumor growth.